F. Khandan

发表

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

Carsten Denkert, Peter A Fasching, Andreas Schneeweiss, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial

P. Fasching, T. Fehm, S. Loibl, 2011, British Journal of Cancer.

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).

M. Rezai, P. Fasching, H. Tesch, 2013, European journal of cancer.

Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.

C. Denkert, M. Dietel, J. Budczies, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

M. Rezai, P. Fasching, A. Schneeweiss, 2014, The Lancet. Oncology.

Abstract S4-06: PIK3CA mutation predicts resistance to anti-HER2/chemotherapy in primary HER2-positive/hormone-receptor-positive breast cancer – Prospective analysis of 737 participants of the GeparSixto and GeparQuinto studies

M. Rezai, P. Fasching, A. Schneeweiss, 2013 .

Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer

C. Denkert, M. Dietel, J. Budczies, 2012, British Journal of Cancer.

A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto).

M. Rezai, S. Jud, A. Schneeweiss, 2013 .

Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

C. Denkert, H. Tesch, S. Loibl, 2010, Breast Cancer Research and Treatment.

Abstract S2-04: Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)

M. Rezai, P. Fasching, A. Schneeweiss, 2016 .

Neutrophil Gelatinase-Associated Lipocalin (NGAL) Predicts Response to Neoadjuvant Chemotherapy and Clinical Outcome in Primary Human Breast Cancer

C. Denkert, W. Jonat, S. Loibl, 2012, PloS one.

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.

M. Rezai, T. Fehm, T. Kühn, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.